e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma
Ciaran O'Neill, Peter G. Gibson, Liam G. Heaney, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Christine R. Jenkins, Matthew Peters, Guy B. Marks, Alan L. James, Jodie L. Simpson
Source:
Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ciaran O'Neill, Peter G. Gibson, Liam G. Heaney, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Christine R. Jenkins, Matthew Peters, Guy B. Marks, Alan L. James, Jodie L. Simpson. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
Could montelukast reduce asthma exacerbations?
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
Long-term azithromycin therapy in severe COPD with repeated exacerbations
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010
Recommendations on long-term antibiotics and mucolytics for prevention of exacerbations of COPD
Source: International Congress 2017 – Treatment and prevention of COPD exacerbation
Year: 2017
Efficacy and safety of intravenous montelukast in patients with acute exacerbations of bronchial asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
The direct costs of exacerbations in COPD and the effect of cilomilast treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Efficacy and safety of various antimicrobial regimens in the treatment of acute exacerbations of chronic bronchitis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003
Long-term benefits of antibiotic treatment in reducing recurrence rates and resource utilization in acute exacerbations of chronic bronchitis (AECB)
Source: Annual Congress 2003 - Outcome of acute exacerbations in COPD
Year: 2003
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019
Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019
Year: 2019
Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Macrolides in the prevention of COPD exacerbations
Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease
Year: 2012
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Perceived bronchodilator efficacy during severe asthma exacerbations
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept